Depression is a common but serious illness, which is described as a state of low mood or mood disorder that involves feelings of sadness lasting for two weeks or longer\[^{[1]}\]. Depressed people may suffer from a spectrum of syndromes, including change of sleep habituation or pattern, dramatic weight loss, cognitive impairments or even suicide. One conventional antidepressant medication is selective serotonin re-uptake inhibitor\[^{[2, 3]}\]. However, the weeks delay of its efficacy constitutes the major drawback of this treatment\[^{[3]}\]. Therefore, fast-acting antidepressants are urgently needed for clinical treatment of depression. Autry \textit{et al} reported in a recent issue of \textit{Nature} that \textit{N}-methyl-D-aspartate receptor (NMDAR) antagonists could be such candidates by triggering rapid behavioural antidepressant responses\[^{[4]}\].

It was previously observed that patients with major depressive disorder symptoms could be relieved shortly after a single low-dose intravenous infusion of ketamine, a non-competitive NMDAR antagonist, with the effects lasting up to two weeks\[^{[5, 6]}\]. This exciting observation inspires the authors to investigate the underlying cellular mechanisms. The authors first found that non-competitive NMDAR antagonists ketamine, CPP and MK-801 reduced immobility of wild-type C57BL/6 mice in notable behavioural responses, such as the forced swim test (FST) and novelty-suppressed feeding (NSF), and the antidepressant-like behavioural effects of ketamine and CPP emerged as early as 30 min after the administration and persisted for at least 24 h. Because NMDAR antagonists applied acutely \textit{in vivo} are eliminated within hours, it is more likely that the long-lasting antidepressant effects come from synaptic plasticity caused by the acute blockade of NMDAR. Brain-derived neurotrophic factor (BDNF) has been proved to be involved in both synaptic plasticity and antidepressant action\[^{[7, 8]}\]. This study further demonstrated that fast-acting antidepressant responses required rapid increase in the translation of BDNF protein and TrkB activation, which might in turn initiate synaptic plasticity. Many forms of activity-dependent plasticity require NMDAR activation\[^{[9]}\]. Thus, blockade of NMDAR does not seem to be in favor of triggering plasticity that might underlie the fast-acting antidepressant responses.

It has been found that the spontaneous and evoked forms of glutamatergic activity may utilize distinct signaling pathway\[^{[10, 11]}\]. It is possible that NMDAR blockade would initiate a different signaling pathway that depends on spontaneous activity. Eukaryotic elongation factor 2 (eEF2) is a critical catalytic factor for ribosomal translation during protein synthesis. It has been proposed that NMDAR activity at rest would affect eEF2 phosphorylation and subsequent translation of target transcripts\[^{[12]}\]. The authors demonstrated that ketamine at rest inhibited spontaneous mEPSCs and dose-dependently de-phosphorylated eEF2, allowing translation of target proteins. These results demonstrated that ketamine’s rapid antidepressant effect results from inhibition of NMDAR-mediated spontaneous synaptic responses, leading to decreased eEF2K activity and subsequent attenuated eEF2 phosphorylation, which in turn rapidly increases BDNF translation.

The authors elegantly elucidate the cellular mechanisms underlying fast-antidepressant responses of a single, low-dose intravenous infusion of ketamine under clinical treatment and provides the first evidence that tonic resting glutamatergic neurotransmission is involved in behavior. Moreover, this study shed new light on the potential of therapeutic approaches on translational machinery. eEF2 is proposed to be the key molecule involved in synaptic BDNF translation that act downstream of NMDAR blockade and could be novel therapeutic targets for the development of faster-acting antidepressants.

Future challenge will be to examine the possible involvement of extrasynaptic NMDAR blockade in the fast-acting antidepressant responses. Ambient
tonic NMDAR activation by extracellular glutamate has been detected under basal condition\[13\]. Ketamine can abolish both spontaneous synaptic and extrasynaptic NMDAR responses. Recent evidence suggests that activation of extrasynaptic NMDAR induces neuronal death in pathological conditions, whereas synaptic NMDAR promotes neuronal survival in physiological conditions\[14, 15\]. Blockade of spontaneous activity of the extrasynaptic NMDARs might be able to trigger a distinct signaling pathway involving eEF2. In addition, previous studies support the involvement of cortical mTOR signaling in ketamine-mediated antidepressant responses and the blockade of the responses by rapamycin\[16\]. These findings are obviously inconsistent with the results of this study. More works are needed to resolve the discrepancies. Moreover, considering the fundamental roles of NMDAR in neuronal functions, possible side effects should be also mindful if the period of clinical ketamine treatment needs to be prolonged.

1 Frances A. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American psychiatric press 2000, p 354–6.
2 Neumeister A, Nugent AC, Waldeck T, Geraci M, Schwarz M, Bonne O, et al. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiat 2004; 61: 765–73.
3 Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137–51.
4 Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P, et al. NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature 2011; 475: 91–5.
5 Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351–4.
6 Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009; 66: 522–6.
7 Kovalchuk Y, Hanse E, Kafitz KW, Konnerth A. Postsynaptic induction of BDNF-mediated long-term potentiation. Science 2001; 295: 1729–34.
8 Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251–61.
9 Bear MF, Malenka RC. Synaptic plasticity: LTP and LTD. Curr Opin Neurobiol 1994; 4: 389–99.
10 Sutton MA, Schuman EM. Partitioning the synaptic landscape: distinct microdomains for spontaneous and spike-triggered neurotransmission. Sci Signal 2009; 2: pe19.
11 Atasoy D, Ertunc M, Moulder KL, Blackwell J, Chung C, Su J, et al. Spontaneous and evoked glutamate release activates two populations of NMDA receptors with limited overlap. J Neurosci 2008; 28: 10151–66.
12 Sutton MA, Taylor AM, Ito HT, Pham A, Schuman EM. Postsynaptic decoding of neural activity: eEF2 as a biochemical sensor coupling miniature synaptic transmission to local protein synthesis. Neuron 2007; 55: 648–61.
13 Sah P, Hestrin S, Nicoll RA. Tonic activation of NMDA receptors by ambient glutamate enhances excitability of neurons. Science 1989; 246: 815–8.
14 Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002; 5: 405–14.
15 Hardingham GE, Bading H. The yin and yang of NMDA receptor signalling. Trends Neurosci 2003; 26: 81–9.
16 Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959–64.